| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 97.58 | 36.1% |
| Total Income | 98.75 | 34.8% |
| Expenditure | 112.68 | 36.6% |
| PBT | -13.93 | 51.2% |
| Net Profit | -14.22 | 47.1% |
| OPM | -10.33% | 2.26pp |
| NPM | -14.40% | 1.21pp |
| EPS | 1.54 | 46.7% |
Themis Medicare Ltd Reports 6.22% YoY Revenue Growth in FY 2024-25, Despite API Business Headwinds
18 Aug 2025 · 18 Aug 2025, 07:12 pm
Summary
Themis Medicare Ltd has reported a 6.22% YoY revenue growth in FY 2024-25, with the Formulations segment growing over 20% YoY and the Hospital Business growing over 13% YoY. The Trade Business also posted over 45% YoY growth in Q2. Despite headwinds in the API business, the company maintained business resilience through cost efficiency, sourcing optimization, and structural realignment efforts. The revenue for the year 2024-25 stood at Rs. 405.51 crores, with EBITDA and PAT at Rs. 49.05 crores and Rs. 29.83 crores, respectively.
Key Highlights
- 1
Revenue increased 6.22% YoY to Rs. 405.51 crores
- 2
EBITDA and PAT stood at Rs. 49.05 crores and Rs. 29.83 crores, respectively
- 3
Formulations segment grew over 20% YoY
- 4
Hospital Business grew over 13% YoY
- 5
Trade Business posted over 45% YoY growth in Q2
- 6
API business faced headwinds from pricing pressures in China and domestic players
Management Comments
Managing Director & CEO
Our performance through this fiscal year reflects our unwavering commitment to innovation, operational excellence and strategic foresight... We remain committed to building a future-ready organization — one that is agile, efficient and focused on creating sustained value for patients, healthcare providers and stakeholders alike.
Informational and educational content only. Not investment advice.